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The exocrine and endocrine pancreata are very closely linked both anatomically and physiologically.
Abdominal symptoms such as nausea, bloating, diarrhea, steatorrhea, and weight loss can often occur in
diabetic patients. Impairments of the exocrine pancreatic function seem to be a frequent complication of
diabetes mellitus; however, they are largely overlooked. The aim of this paper is to provide an overview
of the current concepts of exocrine pancreatic insufﬁciency (PEI) in diabetes mellitus. The prevalence and
symptoms of PEI in diabetes mellitus, the pathomechanism, and difﬁculties of diagnosis and therapy of
PEI are summarized in this systematic review.
© 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.Introduction
The exocrine and endocrine pancreata are very closely linked
both anatomically and physiologically. Pathological conditions in
the exocrine tissue can therefore cause an impairment of endocrine
function and vice versa [1]. Pancreatic exocrine insufﬁciency (PEI) is
deﬁned by a deﬁciency of exocrine pancreatic enzymes resulting in
an inability to maintain normal digestion [2]. The primary function
of pancreatic enzymes is the hydrolysis of proteins (trypsinogens,
proelastase, mesotrypsin), carbohydrates (a-amylase), lipids
(lipase) and nucleotids (DNase, RNase). Chronic pancreatitis is the
most common etiology of PEI. Gastrointestinal and pancreatic
surgical resections, cystic ﬁbrosis, obstruction of the main pancre-
atic duct (e.g. pancreatic and ampullary tumors), decreased
pancreatic stimulation (e.g. celiac disease), or acid-mediated inac-
tivation of pancreatic enzymes (e.g. Zollinger-Ellison syndrome)
can lead to PEI [3]. Furthermore, PEI has been demonstrated to be
present in a considerable percentage (10e74%) of patients with
diabetes mellitus [4,5]. However, the signiﬁcance of this ﬁndings
was questioned and it is not clear, whether the presence of diabetes
causes any symptoms or requires any treatment [6].
Abdominal symptoms such as nausea, bloating, diarrhea,Zsori).
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These symptoms may be attributed to the side-effects of the met-
formin they are taking, the autonomic neuropathy on bowel func-
tion, small bowel bacterial overgrowth, celiac disease, or PEI.
Impairments of the exocrine pancreatic function seem to be a
frequent complication of diabetes mellitus; however, they are
largely overlooked. Greater knowledge and awareness are required
in testing and diagnosing this condition. Previous studies have
raised the possibility that the replacement of pancreatic enzymes in
exocrine insufﬁciency improves related symptoms and may aid
glucose control.
The aim of this paper is to provide an overview of the current
concepts of PEI in diabetes mellitus.Search strategy
The systematic review was conducted following the preferred
reporting items for systematic review and meta-analysis protocols
(PRISMA-P) 2015 statement [7]. A systematic search was performed
in 3 databases, Pubmed, Embase and Cohraine Library. The search
included the following MESH terms: “diabetes mellitus” AND
“pancreatic function” OR “pancreatic exocrine insufﬁciency” OR
“fecal elastase” OR “secretin” OR “cholecystokinin” OR “steator-
rhea” or “pancreatic enzyme replacement therapy”. The search was
limited to human data and to full text English articles if appropriate.
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Selection of the studies was conducted by two investigators
(G.Zs. and L.C.) separately. Clinical studies were eligible provided
that they reported the data of pancreatic exocrine function in adult
patients suffering from type 1 and 2 diabetes mellitus. Publications
about type III/C diabetes were excluded. Duplicates, repeated
publications, publications available only in abstract form, and re-
view papers were excluded. Moreover, articles with inappropriate
study design and patient inclusion criteria were also excluded from
this systematic review. Remaining studies were further analyzed in
full text. The reference list of obtained articles was also checked for
additional articles. If differences were found in the reviewer's
judgement, then a committee of three other researchers was
invited to draw a conclusion. Database searches yielded altogether
1055 articles (EMBASE: 67; PubMed: 701; Cochrane: 287). The
ﬂow-chart diagram (Fig. 1) shows the strategy and results of the
study selection.Prevalence of exocrine pancreatic insufﬁciency in diabetes
mellitus
There have been numerous reports in recent decades on PEI in
patients with diabetes mellitus. In the early studies, pancreatic
exocrine function was assessed with the gold-standard method of
direct pancreatic function tests (pancreozymin-secretin test). PEI
was revealed in 52.4% (18e100%) of the cases (Table 1a) [6,8e15].
However, these studies were only limited to a small number of
patients because direct pancreatic function tests are invasive, time-
consuming and expensive.
Therefore, a less invasive, cost-effective test was needed to
evaluate pancreatic exocrine function in DM. Fecal elastase-1 (FE-1)
test measures fecal levels of elastase-1, a proteolytic enzyme pro-
duced by pancreatic acinar cells. Fecal level of elastase-1 correlates
with the output of other pancreatic enzymes, it is highly stable inFig. 1. The ﬂow-chart diagram shows t
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and speciﬁcity in moderate and severe PEI [17,18]. Nowadays,
therefore, FE-1 measurement has become a screening tool in
determining PEI. The prevalence of PEI has been demonstratedwith
FE-1 measurement with an average of 40% (26e74%) in type 1
diabetes and with an average of 27% (10e56%) in type 2 diabetes
(Table 1b) [4e6,19e32].
The prevalence of PEI in both types of diabetes is very heter-
ogenous. However, most of these studies did not exclude cases with
previous pancreatic disease, thus leading to a possible bias. In two
recent studies, the prevalence of PEI in DM was less frequent than
in previous studies, probably because pancreatic (type 3c, accord-
ing to the new classiﬁcation of American Diabetes Association: type
4 [33]) diabetes was excluded [28,29]. Low FE-1 was measured in
only 5.4% of 150 consecutive type 1 and 2 diabetic patients after
excluding patients with excessive alcohol consumption, medical
history of abdominal surgery, other known reasons for malab-
sorption, previous pancreatic disease and DM lasting <5 years [28].
In another recent study, PEI was diagnosed with FE-1 measurement
in 16.8% of type 2 diabetic patients after excluding patients with an
abnormal pancreatic morphology [29]. Indeed, the prevalence of
chronic pancreatic diseases among diabetic patients might be high
because recent discussions have suggested that pancreatic diabetes
(type 4) has been underestimated in the past and that it might
cause about 8% of all diabetes cases [34].Prevalence of morphologic changes of the exocrine pancreas
in diabetes mellitus
Several studies have examined the morphologic changes of the
exocrine pancreas in DM. In nearly 50% of type 1 DM patients, the
pancreas is atrophic and ﬁbrotic, with fatty inﬁltration and loss of
acinar cells on histological examination [35,36]. Reduced pancreas
size in patients with DM was demonstrated by abdominal ultra-
sonography, computed tomography or magnetic resonance imag-
ing (MRI) [37e43]. Ductal changes are detected by endoscopic
retrograde cholangiopancreatography in 76% of diabetics.he strategy of the study selection.
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Table 1A
Results of direct pancreatic function tests in patients with diabetes mellitus.
Author Subjects/diabetes type Methods Results
Pollard et al., 1943 [8] 13 Amylase and lipase after
pancreozymin-secretin stimulation
62% reduced
Chey et al., 1963 [9] 50 diabetic patients; 13 juvenile
type
Amylase and lipase after
pancreozymin-secretin stimulation
Low amylase output in diabetes: 36%;
in juvenile diabetes: 77%
Vacca et al., 1964 [10] 55 diabetic patients
(22 insulin-treated)
Diastase and bicarbonate after secretin
stimulation; fecal fat
73% abnormal; correlation with age, no
correlation with fecal fat
Frier et al., 1976 [11] 20 type 1, 7 type 2, 13 controls Stimulation with iv secretin and CCK-PZ PEI: 80% IDDM; correlation with
diabetes duration
Harano et al., 1978 [12] 53 type 2, 4 type 1, 18 controls Secretin-pancreozymin test Diabetes: 69% deﬁcient enzyme output;
correlation with diabetes control
Lankisch et al., 1982 [13] 53 type 1 Secretin-pancreozymin test Diabetes: 43% impaired function
Bretzke et al., 1984 [14] 60 insulin-treated type 2
diabetic patients
Secretin-pancreozymin test Diabetes: 27% “mild PEI”
El Newihi et al., 1988 [15] 10 type 2 diabetic patients with
diarrhea and neuropathy
Secretin and CCK test Enzyme and bicarbonate reduction in
all subjects
Hahn et al., 2008 [6] 33 type 1 Secretin and CCK test 33% mild enzyme reduction
CCK-PZ: Cholecystokinin-pancreozymin; IDDM: Insulin-dependent diabetes mellitus; PEI: Exocrine pancreatic insufﬁciency.
Table 1B
Results of indirect pancreatic function tests in patients with diabetes mellitus.
Author Subjects/diabetes type Methods Results




Hardt et al., 2000 [5] 39 type 1
77 type 2
Fecal elastase 1 74%< 200 mg/g
36%< 200 mg/g
Icks et al., 2001 [20] 112 type 1 Fecal elastase 1 54.5%< 200 mg/g
Rathmann et al., 2001 [21] 544 type 2 Fecal elastase 1 30.3%< 200 mg/g
Hardt et al., 2003 [22] 323 type 1
697 type 2
Fecal elastase 1 51%< 200 mg/g
35%< 200 mg/g
Nunes et al., 2003 [23] 42 type 1 and 2 Fecal elastase 1 36%< 200 mg/g
Cavalot et al., 2004 [24] 66 type 1 Fecal elastase 1 26%< 200 mg/g
Yilmaztepe et al., 2005 [25] 32 type 2 Fecal elastase 1 28%< 200 mg/g
Ewald et al., 2007 [26] 546 type 2 Fecal elastase 1 21.1%< 100 mg/g
Hahn et al., 2008 [6] 33 type 1 Fecal elastase 1 33%< 200 mg/g
Larger et al., 2012 [27] 195 type 1, 472 type 2 Fecal elastase 1 23%< 200 mg/g
Vujasinovic et al., 2013 [28] 50 type 1, 100 type 2 Fecal elastase 1 5.4%< 200 mg/g
Terzin et al., 2014 [29] 101 type 2 Fecal elastase 1 16.8%< 200 mg/g
Cummings et al., 2015 [4] 288 type 2 Fecal elastase 1 10%< 200 mg/g
Shivaprasad et al., 2015 [30] 89 type 1, 95 type 2 Fecal elastase 1 31%< 200 mg/g
Kangrga et al., 2016 [31] 315 type 2 Fecal elastase 1 5.1%< 100 mg/g and 5.1%< 200 mg/g
Oscarsson et al., 2017 [32] 10 type 1, 38 type 2 Fecal elastase 1 33%< 200 mg/g
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DM duration or age (Table 2) [35e48].
Pathophysiology
The mechanism of exocrine pancreatic insufﬁciency in diabetes
is multifactorial (Fig. 2). Pancreas atrophy is a related event in DM
and plays a central role in the development of PEI. (1) Insulin has a
trophic effect on pancreatic acinar tissue through the insulin-acinar
portal system, so its decreased locally high level could lead to
pancreatic atrophy [49]. Moreover, decreased pancreatic volume
and PEI were shown to correlate in patients with DM [43,50,51]. (2)
Acute hyperglycemia was demonstrated to inhibit basal and
cholecystokinin-stimulated pancreatic enzyme secretion with an
insulin-independent mechanism [52]. (3) Pancreatic stellate cells
(PSCs) play a pivotal role in pancreatic ﬁbrosis. Hyperglycemia was
demonstrated to promote proliferation and activation of PSCs and
to stimulate collagen production of PSCs via the protein kinase seC-
p38 mitogen-activated protein kinase pathway, resulting in
pancreatic ﬁbrosis [53]. (4) The islet hormones (e.g. glucagon and
somatostatin) can regulate exocrine tissue, so the lack of these
hormones causes dysregulation of enzyme synthesis and resultant
exocrine insufﬁciency. (5) Diabetic microangiopathy leads to
insufﬁcient perfusion through local microangiopathy, resulting inPlease cite this article in press as: Zsori G, et al., Exocrine pancreatic insufﬁ
systematic review, Pancreatology (2018), https://doi.org/10.1016/j.pan.20ischemia of the exocrine pancreas, which could lead to pancreatic
ﬁbrosis, atrophy and PEI [29]. (6) Autonomic neuropathy may give
rise to impaired enteropathic reﬂexes and PEI [27,54,55]. Moreover,
(7) viral infections [56], (8) autoimmunity [57], or (9) genetic
changes, as single-base deletion in the variable number of tandem
repeats containing exon 11 of the carboxyl ester lipase gene [58]
could increase simultaneous damage to exocrine and endocrine
tissue.
The higher prevalence of PEI in type 1 diabetes can be explained
by the more severe insulin deﬁciency, longer disease duration, and
higher rate of microvascular complications characterized by type 1
DM.
The correlation between diabetes duration and the prevalence
of PEI is contradictory. Previous studies have described an associ-
ation or at least aweak correlation between low FE-1 level in type 2
DM and age of onset of diabetes, relatively long diabetes duration,
and relatively high glycosylated hemoglobin (HbA1c) concentra-
tion, suggesting that exocrine dysfunction is a long-term compli-
cation of diabetes [22,59]. However, studies have demonstrated
that there is no relationship between fecal elastase concentration
and diabetes duration [60]. Otherwise, an inverse correlation was
described between diabetes duration and HbA1c levels, and a
positive correlation was reported between C-peptide and FE-1
levels [59]. A long-term follow-up study suggested that a mild tociency in type 1 and type 2 diabetesmellitus: dowe need to treat it? A
18.05.006
Table 2
The prevalence of morphologic changes of the exocrine pancreas in diabetes mellitus.
Author Year Subjects Methods Results
Blumenthal HT et al. [44] 1963 3821 autopsy cases Morphology Prevalence of pancreatitis:
- In diabetics: 11.2%;
- In non-diabetics: 5.3%




- In diabetics: 75%;
- In controls: 60%
Gilbeau JP et al. [37] 1992 20 type 1, 37 type 2 CT scans Pronounced lobulation, small size compared to controls
Alzaid A et al. [39] 1993 14 type 1, 43 type 2 Ultrasound Small size compared to controls; type1<type2<controls
Nakanishi K et al. [40] 1994 36 type 1, 43 type 2 ERCP Changes like CP:
- type 1: 40%
- type 2: 9%
Kl€oppel G et al. [36] 1996 type 1 Histology Fibrosis, atrophy, fatty inﬁltration
Foulis AK et al. [35] 1997 type 1 Histology Fibrosis, atrophy, fatty inﬁltration
Altobelli E et al. [38] 1998 60 type 1 Ultrasound Small size compared to controls; dependent on duration
Hardt PD et al. [41] 2002 38 type 1, 118 type 2 ERCP Changes like CP:
type 1> type 2, up to 75%
Williams et al. [47] 2007 12 male patients with type 1 and 12
healthy controls
MRI Pancreatic volume showed a 48% reduction in long-standing
type 1 diabetes as compared with age-matched normal subjects.
Bilgin M et al. [42] 2009 82 type 1 and type 2 MRI/MRCP Changes like CP
Philippe et al. [43] 2011 24 type 1 and 28 type 2 CT scans The pancreatic volume, 42 cm (25e57 cm), was decreased in
most patients
Williams et al. [48] 2012 20 male
recent-onset type 1 diabetes patients
and 24 male healthy controls
MRI Pancreatic volume is reduced by 26% in type 1 diabetes
Burute N et al. [46] 2014 32 type 2 and 50 normoglycemic
individuals
MRI Patients with type 2 DM had signiﬁcantly lower pancreatic
volume than normoglycemic individuals (p< 0.001)
ERCP: endoscopic retrograde cholangiopancreatography; CP: chronic pancreatitis; CT: computed tomography;MRI:Magnetic Resonance Imaging;MRCP: Magnetic Resonance
Cholangiopancreatography.
Fig. 2. The mechanism of exocrine pancreatic insufﬁciency in diabetes mellitus.
G. Zsori et al. / Pancreatology xxx (2018) 1e74moderate exocrine pancreatic insufﬁciency is due to an early event
in the course of DM and does not progress [61].
Nowadays the role of signaling proteins in pancreatic inﬂam-
mation and diabetes induced pancreatic insufﬁciency is getting
more attention. In a previous study the levels of total PKB, p70S6K,
4 E-BP1, ERK1/2, and NF-kappaB in the diabetic pancreas compared
to control were signiﬁcant decreased, however, the phosphoryla-
tion of p70S6K1, 4 E-BP1, ERK1/2, and protein ubiquitination were
increased signiﬁcantly compared to control group [62]. Presumable,
that these factors are liable for decreased enzyme synthesis and
pancreatic atrophy.Symptoms of PEI in diabetes
The main clinical symptoms of PEI are due to the maldigestion
and malabsorption of fat, including steatorrhea, abdominal pain,Please cite this article in press as: Zsori G, et al., Exocrine pancreatic insufﬁ
systematic review, Pancreatology (2018), https://doi.org/10.1016/j.pan.20ﬂatulence, bloating and weight loss [4]. As a consequence of
malnutrition, PEI is associated with low serum levels of micro-
nutrients, lipid soluble vitamins (vitamins A, D, E, and K), trace
elements, albumin, prealbumin and lipoproteins [2,29,63e74]. The
low level of serumvitamin D leads to osteoporosis and an increased
risk of fractures [75]. Protein-energy malnutrition and malabsorp-
tion of vitamin D and other micronutrients may result in a higher
risk of infection due to their associated effects on innate and
adaptive immune responses [76].
Although PEI seems to be frequent in DM, data on the occur-
rence of the symptoms of PEI in diabetes are limited. Gastrointes-
tinal (GI) symptoms are common (27e87%) in patients with type 1
and type 2 DM [77e79]. In a recent study by Cummings et al. [4],
24% of diabetic patients had one or more GI symptoms consistent
with a diagnosis of PEI (Bristol stool type 5e7, steatorrhea or weight
loss). Among these patients, 42% had a low FE-1, indicating PEI. Itciency in type 1 and type 2 diabetesmellitus: dowe need to treat it? A
18.05.006
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GI symptoms, suggesting the presence of PEI. Furthermore, steat-
orrhea was a poor marker of PEI in diabetes in this study, since only
the minority of patients with steatorrhea had a low fecal elastase
level. One would logically expect that diabetic patients with PEI
experience weight loss, lower body weight and BMI. However,
there were no signiﬁcant differences in BMI between diabetic pa-
tients with a decreased or normal PE-1 concentration [4,29].
Inconsistent with these ﬁndings, the size of the pancreas did not
correlate with BMI among diabetic patients in another study [37].
Furthermore, PEI detected by low FE-1 concentrations is frequent
even in obese diabetic patients [23,80], and diabetic individuals
with excess weight (BMI >25) may be at increased risk for PEI [25].
Diagnosis of PEI
PEI is suggested by clinical symptoms or poor glycemic control
despite an adequate diet, antidiabetic therapy and patient adher-
ence [24,29]. Determination of FE-1 is the most convenient way to
diagnose PEI. Decreased FE-1 concentration has previously been
demonstrated to be a sensitive method in moderate and severe PEI
(sensitivity: 87% and 95%, respectively) and correlated signiﬁcantly
with the direct pancreatic function test, fat digestion, and the
Cambridge severity classiﬁcation of chronic pancreatitis [81e83].
FE-1 concentration correlates with the severity of PEI: a level of less
than 200 mg/g stool indicates moderate PEI, while a level of less
than 100 mg/g stool indicates severe PEI [84]. FE-1 is not sufﬁciently
sensitive in mild PEI, but if FE-1 level is decreased, there is a strong
chance of revealing changes in the pancreatic duct system and
steatorrhea [83,85].
PEI can also be diagnosed with a 13C mixed triglyceride breath
test by measuring the concentration of 13CO2 in expired air after
administering the radiolabeled test meal containing a known
amount of fat [86]. Its accuracy is similar to FE-1 in diagnosing PEI
[87].
Coefﬁcient of fat absorption (CFA) is another gold standard test
for PEI [88], although it has not been evaluated in DM. During the
72-h stool collection period, the patient consumes 100 g of fat per
day. Fat malabsorption is diagnosed at >7 g of fat/100 g of stool/day,
with severe steatorrhea at15 g/day. However, the diet is
cumbersome, the 3-day stool collection is inconvenient for both
patients and laboratory staff, and therefore CFA is not used in daily
clinical practice. It is utilized to evaluate the effectiveness of
pancreatic enzyme replacement therapy (PERT) in PEI [89].
Direct pancreatic function tests are considered the gold stan-
dard in diagnosing PEI, and they deﬁnitely have advantages over
indirect tests. However, direct tests are rather time-consuming and
expensive to perform, very inconvenient for patients, and only
available in a few academic centers.
Therapy
PERT is applied in PEI to prevent the symptoms of malabsorp-
tion, such as steatorrhea, and to provide physiologic nutrition by
correctingmaldigestion. Only a very limited number of publications
have investigated the effectiveness of PERT in PEI associated with
diabetes, and the results are contradictory. Three small trials
studied the efﬁcacy of PERT in patients with diabetes mellitus
secondary to chronic pancreatitis [90,91]. Treatment with PERT
demonstrated a signiﬁcant reduction in post-prandial plasma
glucose and glycosylated hemoglobin at 6 months versus baseline
values in patients with diabetes due to tropical calculous pancre-
atitis [92]. In contrast, PERT did not improvemean glucose values; it
produced potentially life-threatening disturbances in glucose con-
trol among insulin-dependent diabetic patients due to chronicPlease cite this article in press as: Zsori G, et al., Exocrine pancreatic insufﬁ
systematic review, Pancreatology (2018), https://doi.org/10.1016/j.pan.20pancreatitis [93]. However, a recent double-blind, randomized,
placebo-controlled trial of PERT in patients with PEI due to chronic
pancreatitis demonstrated that the efﬁcacy outcomes and adverse
event proﬁle for PERT were comparable between patients with and
without diabetes [94]. A larger multicenter, double-blind, ran-
domized, placebo-controlled trial demonstrated that PERT was
safe, but has no effect on glycemic control in insulin-treated dia-
betic patients with FE-1 <100 mg/g [26]. Reduction in mild to
moderate hypoglycemic episodes was revealed after 16 weeks of
treatment with four capsules of 10 000 FIP units of pancreatin with
main meals and two capsules of 10 000 FIP units of pancreatinwith
snacks, suggesting a more stable control of insulin therapy. How-
ever, this study might be criticized. First, patients were selected
according to the presence of PEI irrespective of PEI-related symp-
toms. Second, the applied dose of pancreatin might be low. Recent
guidelines [93e96] recommend a starting dose of PERT to be
50 000 IU lipase per main meal and 25 000 IU per snack, and this
may be titrated up according to symptoms. However, recent evi-
dence suggests that even this dose of PERT may not be sufﬁcient to
normalize nutrition [94,97].
Nutrient-induced glucose-dependent insulinotropic poly-
peptide (GIP) response is diminished in patients with PEI [98]. PERT
has been demonstrated to reverse an impaired GIP response and
therefore to restore the incretin effect of fat [98]. This effect of PERT
may be beneﬁcial in the glycemic control of diabetic patients with
PEI.
However, while diabetic patients with reduced FE-1 may not
complain about PEI-related gastrointestinal symptoms, they still
might suffer from qualitative fat maldigestion, for example, lack of
vitamin D, as has been proposed recently [99]. Furthermore, pa-
tients with diabetes mellitus have an increased risk of bone frac-
tures [100]. PERT has been demonstrated to increase serumvitamin
D level in diabetic patients with PEI, an effect which would be
beneﬁcial to reducing the increased risk of bone fracture [26].
However, there are several limitations to this systematic review.
Firstly, the prevalence of PEI in both types of diabetes is very
heterogenous, ranging between 5.1 and 80%. Secondly, studies
applied the gold standard direct pancreatic function test in the
measurement of PEI are limited to a small number of patients
because of the invasive nature of the test. Thirdly, most of these
studies did not exclude cases with previous pancreatic disease, thus
leading to a possible bias. Fourth, PEI seems to be frequent in DM,
data on the occurrence of the symptoms of PEI in diabetes are
limited. Furthermore, only a very limited number of publications
have investigated the effectiveness of PERT in PEI associated with
diabetes, and the results are contradictory.
Conclusion
The currently available evidence is limited to answering the
question of whether PERT is efﬁcacious in glycemic control in pa-
tients with diabetes and PEI. Without doubt, there is a need for
further randomized clinical trials in the ﬁeld. For the moment, we
can only suggest searching for PEI in diabetic patients by looking for
abdominal symptoms that may be related to PEI and by analyzing
serum nutritional factors and vitamin D level. If the test is positive,
a trial of PERT is recommended. The response of abdominal
symptoms, serum nutritional factors and parameters of glucose
metabolism should be followed. In the case of positive response,
long-term PERT is suggested.
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